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Background: The extent to which physiological factors influence outcome following oesophageal cancer
surgery is poorly understood. This study aimed to evaluate the extent to which cardiorespiratory fitness
and selected metabolic factors predicted complications after surgery for carcinoma.
Methods: Two hundred and twenty-five consecutive patients underwent preoperative cardiopulmonary
exercise testing to determine peak oxygen uptake (V̇O2peak), anaerobic threshold and the ventilatory
equivalent for carbon dioxide (V̇E/V̇CO2). Cephalic venous bloodwas assayed for serumC-reactive protein
(CRP) and albumin levels, and a full blood count was done. The primary outcome measure was the
Morbidity Severity Score (MSS).
Results: One hundred and ninety-eight patients had anatomical resection. A high MSS (Clavien–Dindo
grade III or above) was found in 48 patients (24⋅2 per cent) and was related to an increased CRP
concentration (area under the receiver operating characteristic (ROC) curve (AUC) 0⋅62, P = 0⋅001) and
lower V̇O2peak (AUC 0⋅36, P = 0⋅003). Dichotomization of CRP levels (above 10mg/l) and V̇O2peak (below
18⋅6ml per kg per min) yielded adjusted odds ratios (ORs) for a high MSS of 2⋅86 (P = 0⋅025) and 2⋅92
(P = 0⋅002) respectively. Compared with a cohort with a low Combined Inflammatory and Physiology
Score (CIPS), the OR was 1⋅70 (95 per cent c.i. 0⋅85 to 3⋅39) for intermediate and 27⋅47 (3⋅12 to 241⋅69)
for high CIPS (P< 0⋅001).
Conclusion: CRP and V̇O2peak were independently associated with major complications after potentially
curative oesophagectomy for cancer. A composite risk score identified a group of patients with a high risk
of developing complications.
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Introduction
Oesophagectomy remains the primary therapeutic modal-
ity for potentially curative treatment for patients with
oesophageal cancer. Despite recent advances in anaes-
thesia and critical care, it continues to be associated
with considerable morbidity. The 2018 UK National
Oesophago-Gastric Cancer Audit1 reported postop-
erative morbidity and mortality rates of 50 and 1⋅6
per cent respectively. A number of approaches to
risk prediction have been proposed in addition to
clinical judgement: objective scoring systems such as
Portsmouth POSSUM (P-POSSUM)2, Oesophagogastric
POSSUM (O-POSSUM)3, ASA physical status, Charlson
Co-morbidity Index, serum biomarkers4, measures of
cardiac function5 and shuttle walk tests6.
Cardiopulmonary exercise testing (CPET) is a
non-invasive and dynamic procedure that allows an
individual’s cardiopulmonary fitness to be measured
accurately7. CPET, in particular an anaerobic threshold
of less than 11ml per kg per min, has been reported
to predict postoperative morbidity and mortality in
patients undergoing major abdominal surgery8–10. While
established in cardiothoracic surgery11, the application
of CPET in the setting of oesophageal cancer surgery is
limited10,12.
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Inflammation is a hallmark of cancer13, and can be mea-
sured using cellular (neutrophils, lymphocytes, platelets)
and humoral (C-reactive protein (CRP) and albumin) com-
ponent measurements3. Despite emerging evidence that
the systemic inflammatory response (SIR) is associated with
postoperative morbidity in colorectal cancer4,14, confirma-
tory evidence in oesophageal cancer is sparse15.
In view of the above, the present study examined the
extent to which select measures of cardiorespiratory fitness
and metabolic markers of inflammation can predict clini-
cal outcome in patients with oesophageal cancer scheduled
for elective surgery. The hypothesis was that impaired car-
diorespiratory fitness and raised CRP levels would predict
patient morbidity. The primary outcome measure was the
postoperative Morbidity Severity Score (MSS).
Methods
Ethical approval was sought from the regional ethics com-
mittee, but a formal application was deemed unnecessary
because the study was considered to be a service evaluation
of consecutively recruited patients, for whom consent had
already been provided.
Patients
A single cohort of patients diagnosed with oesophageal
cancer between 1 January 2009 and 31 March 2020
was developed; it included patients with radiological
TNM stage I–IV, deemed fit for treatment with cura-
tive intent. Patients were staged using CT, endoscopic
ultrasonography, CT–PET, and staging laparoscopy
as considered appropriate, using patient algorithms for
oesophageal cancer as described previously16,17. The
majority of patients received two cycles of cisplatin
80mg/m2 and 5-fluorouracil (5-FU) 1000mg/m2 for
4 days. A minority received three cycles of epirubicin
50mg/m2, cisplatin 60mg/m2, and 5-FU 200mg/m2 or
capecitabine 625mg/m2.
Surgical intervention
The standard operative approach was open subtotal
transthoracic oesophagectomy (TTO), as described by
Lewis18 and Tanner19. Transhiatal oesophagectomy
(THO), as described by Orringer20, was used selec-
tively in patients with adenocarcinoma of the lower third
of the oesophagus who had significant cardiorespiratory
co-morbidity, cT1–3N0 disease. Laparoscopically assisted
surgery was used for a small number of patients.
Clinicopathological characteristics
Tumours were staged using the seventh edition of the
AJCC/UICC TNM staging system. Pathological factors
were recorded from pathology reports issued at the time of
surgery using the AJCC/UICC TNM staging system (sev-
enth edition), and included tumour differentiation, number
of lymph nodes with and without metastasis, and margin
status.
Routine laboratory measurements of haemoglobin,
whole white cell count, neutrophil count, lymphocyte
count, platelet counts, CRP and albumin on the day before
surgery were recorded. Derivate measurements of systemic
inflammation consisted of the neutrophil/lymphocyte ratio
(NLR) and platelet/lymphocyte ratio (PLR)21,22.
Cardiopulmonary exercise testing
CPET followed American Thoracic Society/American
College of Chest Physicians recommendations11. All
patients performed a symptom-limited CPET conducted
on an electromagnetically braked cycle ergometer; this
comprised a 2–3-min rest phase (to allow gas exchange
variables to stabilize), 3min of unloaded cycling, then a
ramped incremental protocol until volitional termina-
tion, and a 2–5-min recovery period. Ventilation and gas
exchange was measured with a Medgraphics Ultima™
metabolic cart (Medical Graphics, St Paul, Minnesota,
USA) with Breezesuite™ (Medical Graphics) and Welch
Allyn® (Welch Allyn, New York, USA) software, as
described previously12.
Heart rate monitoring, BP, pulse oximetry and 12-lead
ECG were done throughout. The ramp gradient was set
to 10–20W based on the predicted V̇O2peak from the
age, weight, height and sex of the patient, to produce an
exercise test of 8–12min in duration23. Before each test,
the CPET equipment was calibrated against reference
gases. The anaerobic threshold was determined using the
V-slope method and confirmed by changes in ventilatory
efficiency for oxygen (V̇E/V̇CO2) and the end-tidal partial
pressure of oxygen (PetO2)23. The anaerobic threshold
was validated independently by two experienced observers.
V̇O2peak was the highest V̇O2 achieved during the final
30 s of the test. The V̇E/V̇CO2 slope was measured at the
anaerobic threshold. Test termination criteria included:
request of patient, volitional fatigue, chest or leg pain,
or ECG abnormalities determined by the consultant
anaesthetist. Multidisciplinary discussion and stratification
of individual patient risk informed decisions regarding
the planned postoperative level of care and invasive
monitoring.
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Morbidity
Operative morbidity was graded according to the
Clavien–Dindo classification (CDC)24–26. CDC-0 was
a normal postoperative course. CDC-I was any deviation
from the normal postoperative course that was not classi-
fied as grade II and above, and included administration of
antiemetics, antipyretics, analgesics, diuretics, electrolytes
and physiotherapy. CDC-II denoted the need for pharma-
cological interventions not listed as CDC-I, and included
blood transfusion and total parenteral nutrition. CDC-III
was the requirement for surgical, endoscopic or radio-
logical intervention. CDC-IV involved life-threatening
complications requiring ICU management, and CDC-V
was death of the patient. Particular emphasis was placed on
the incidence of morbidity of CDC-III or above, defined
as major morbidity.
Complications were recorded prospectively in a database,
and covered postoperative inpatient stay. They were
diagnosed based on clinical examination and bedside
investigations, supported by radiology and microbiology
assessments.
Patient follow-up
Patients were followed up at 2weeks after discharge, and
then at 3-month intervals for the first year and every
6months thereafter. At follow-up, patients were assessed
for complications and nutritional assessment. Investiga-
tions were undertaken when patients developed symptoms
suggestive of recurrent disease. Surveillance was conducted
for 5 years or until death, whichever occurred first27.
Statistical analysis
Statistical analyses were performed using SPSS® statis-
tics v25.0.0.0 (IBM, Armonk, New York, USA) with
extension R.
Grouped data that were not normally distributed based
on Shapiro–Wilk test were expressed as median (i.q.r.)
values, and non-parametric methods were used. Receiver
operating characteristic (ROC) curve analyses were
employed to assess the predictive value of continuous
variables for the primary outcome measure and thresh-
old, dichotomized for major morbidity as described by
Youden28. For categorical variables, univariable and multi-
variable logistical regression analyses were done to identify
independent associations with major morbidity. Associa-
tions found to be significant (P< 0⋅100) were retained in
a binary logistic regression model using forward condi-
tional methodology. Patient demographics were analysed
Table 1 Incidence of specific complications in patients with
major morbidity (Clavien–Dindo grade III or above)
Complication No. of patients (n = 48)
Respiratory tract infection 36 (75)
Respiratory failure 30 (63)*
Anastomotic leak 23 (48)†
Chylothorax 4 (8)
Wound infection 4 (8)
Pulmonary embolus 3 (6)
Values in parentheses are percentages. *Resulted in one death; †resulted in
four deaths.
between the treatment modalities by means of χ2 or
Mann–Whitney U tests.
Results
In total, 225 patients were identified who had surgery
for oesophageal cancer. Twenty-seven patients (12⋅0 per
cent) were deemed inoperable because of local tumour
invasion, and 198 underwent an anatomical resection. Of
those who had a surgical resection, 106 (53⋅5 per cent)
had a TTO (including 6 3-stage oesophagectomies) and
92 (46⋅5 per cent) a THO. Twenty patients (10⋅1 per
cent) underwent a laparoscopically assisted procedure. The
median age of patients who had an oesophagectomy was 68
(i.q.r. 62–72) years, 170 (85⋅9 per cent) were men, and 183
(92⋅4 per cent) had adenocarcinoma. A total of 138 patients
(69⋅7 per cent) underwent neoadjuvant therapy.
Some 132 patients (66⋅7 per cent) developed a postopera-
tive complication, with 48 (24⋅2 per cent) classified asmajor
(CDC grade III or above). Sixty-one patients (30⋅8 per
cent) had CDC-0, five (2⋅5 per cent) had CDC-I, 84 (42⋅4
per cent) had CDC-II, 23 (11⋅6 per cent) had CDC-III,
20 (10⋅1 per cent) had CDC-IV, and five (2⋅5 per cent)
had CDC-V. The frequency of different complications that
occurred in the major morbidity group is shown in Table 1.
Relationship between markers of systemic
inflammatory response, physiological variables
and Morbidity Severity Score
Baseline and area under the ROC curve (AUC) val-
ues for markers of the systemic inflammatory response
and physiological variables are shown in Table 2. There
was no association between serum CRP and exercise
testing parameters; correlation values for anaerobic
threshold (rS = −0⋅08, P = 0⋅232), V̇O2peak (rS = −0⋅03,
P = 0⋅610) and V̇E/V̇CO2 (rS = −0⋅02, P = 0⋅754) were
not statistically significant. Findings were similar for the
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Table 2 Association between markers of the systemic inflammatory response, physiological variables and major morbidity
No. of patients with level‡ (n = 198)
Median level* Low Normal High AUC† P§
Serum variables
Haemoglobin (g/l) 132 (121–143) 77 121 0 0⋅47 (0⋅38, 0⋅56) 0⋅555
White cell count (×109/l) 6⋅3 (5⋅1–7⋅7) 14 182 2 0⋅59 (0⋅49, 0⋅68) 0⋅070
Neutrophil count (×109/l) 3⋅8 (3⋅0–5⋅0) 10 181 7 0⋅56 (0⋅47, 0⋅66) 0⋅207
Lymphocyte count (×109/l) 1⋅5 (1⋅1–2⋅0) 26 165 7 0⋅54 (0⋅45, 0⋅64) 0⋅367
Platelet count (×109/l) 240 (196–291) 7 187 4 0⋅50 (0⋅41, 0⋅60) 0⋅962
C-reactive protein (mg/l) 3⋅0 (1⋅0–5⋅0) 0 173 25 0⋅62 (0⋅53, 0⋅71) 0⋅012
Neutrophil/lymphocyte ratio 2⋅43 (1⋅77–3⋅33) 0⋅51 (0⋅42, 0⋅60) 0⋅866
Platelet/lymphocyte ratio 155 (120–215) 0⋅46 (0⋅37, 0⋅55) 0⋅364
Cardiopulmonary exercise testing variables
Anaerobic threshold (ml per kg per min) 11⋅7 (10⋅1–13⋅8) 0⋅44 (0⋅34, 0⋅53) 0⋅194
V̇O2peak (ml per kg per min) 20⋅1 (17⋅2–24⋅5) 0⋅36 (0⋅27, 0⋅45) 0⋅003
V̇E/V̇CO2 (ml per kg per min) 30⋅0 (27⋅3–33⋅0) 0⋅60 (0⋅50, 0⋅69) 0⋅053
Values in parentheses are *i.q.r. and †95 per cent confidence intervals. ‡Based on local thresholds. AUC, area under the receiver operating characteristic
(ROC) curve; V̇O2peak, peak oxygen uptake; V̇E/V̇CO2, minute ventilation relative to carbon dioxide production. §P value from ROC analysis.
NLR and PLR (data not shown). Using a dichotomization
value of 10mg/l, 25 (12⋅6 per cent) of the 198 patients
had a raised CRP level. There was no difference between
median measurements of V̇O2peak, anaerobic threshold or
V̇E/V̇CO2 in patients with normal or high CRP concen-
tration respectively. The median value for CRP was 3⋅0
(i.q.r. 1⋅0–5⋅0) mg/l. CRP was strongly associated with
major morbidity (CDC-III or above) (AUC 0⋅62, 95 per
cent c.i. 0⋅53 to 0⋅71; P = 0⋅012) (Table 2 and Fig. 1a). The
median value for V̇O2peak was 20⋅1 (i.q.r. 17⋅2–24⋅5) ml
per kg per min, and that for anaerobic threshold was 11⋅7
(10⋅1–13⋅8) ml per kg per min (Table 2). Using the Youden
index, the optimal dichotomization threshold for V̇O2peak
was 18⋅6ml per kg per min (Fig. 1b) and the anaerobic
threshold was 11⋅5ml per kg per min, with 38⋅4 and 47⋅5
per cent of patients considered to have low measurements
respectively. This gave sensitivity and specificity values of
35⋅5 per cent and 82⋅8 per cent respectively for V̇O2peak,
and 27⋅5 per cent and 79⋅0 per cent respectively for anaer-
obic threshold. Total morbidity (CDC-I or above) rates
were 73⋅7 per cent for low V̇O2peak and 68⋅1 per cent for
low anaerobic threshold respectively.
To adjust for potential confounders, a binary logistic
regression model was developed to include the clinical fac-
tors available to the multidisciplinary team when deciding
on definitive treatment (Table 3). In the univariable analysis,
only CRP (P = 0⋅054) and V̇O2peak (P = 0⋅004) were asso-
ciated with major morbidity. In the multivariable analysis,
CRP (odds ratio (OR) 2⋅86, 95 per cent c.i. 1⋅14 to 7⋅17;
P = 0⋅025) and V̇O2peak (OR 2⋅92, 1⋅47 to 5⋅79; P = 0⋅002)
were independently associated with major morbidity.
A composite score was developed to determine whether
major morbidity could be predicted with greater accu-
racy. This Combined Inflammatory and Physiology Score
(CIPS) ranged from 0 to 2. Patients with a normal CRP
level and V̇O2peak were given a score of zero (low), a score
of 1 (intermediate) was given to patients if either the CRP
concentration was high or V̇O2peak was low, and a score
of 2 (high) was given to patients with both a raised CRP
level and low V̇O2peak. For the 198 patients who had an
anatomical resection, this resulted in 106 (53⋅5 per cent),
85 (42⋅9 per cent) and seven (3⋅5 per cent) patients being
classified with a CIPS that was low, intermediate and high
respectively. Major morbidity rates were 17⋅9 per cent (19
of 106), 27 per cent (23 of 85) and 86 per cent (6 of 7)
in the low, intermediate and high CIPS groups respec-
tively (P< 0⋅001). A stepwise association between increas-
ing CIPS and major morbidity was observed. Compared
with the low CIPS group, the OR was 1⋅70 (95 per cent c.i.
0⋅85 to 3⋅39) for the intermediate CIPS and 27⋅47 (3⋅12 to
241⋅69) for the high CIPS group (P< 0⋅001). The aggre-
gate OR for CIPS and major morbidity was 2⋅52 (1⋅41
to 4⋅50; P = 0⋅002) and increased to 2⋅62 (1⋅42 to 4⋅83;
P = 0⋅002) in those undergoing an open procedure. For
the whole cohort of 225 patients, a higher CIPS was asso-
ciated with a higher frequency of open-and-close proce-
dures, affecting eight of 114 patients (7⋅0 per cent), 11
of 96 (11⋅5 per cent) and eight of 15 (53 per cent) in
the low, intermediate and high CIPS groups respectively
(P< 0⋅001).
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Fig. 1 Receiver operating characteristic (ROC) curves showing predictive value of C-reactive protein and peak oxygen uptake in major
morbidity
0
0·2
0·4
0·6
0·8
1·0
0·2 0·4
1 – specificity
a  C-reactive protein
S
en
si
ti
vi
ty
0·6 0·8 1·0 0
0·2
0·4
0·6
0·8
1·0
0·2 0·4
1 – specificity
b  Peak oxygen uptake
S
en
si
ti
vi
ty
0·6 0·8 1·0
a C-reactive protein; b peak oxygen uptake.
Table 3 Univariable and multivariable binary logistic regression analysis of preoperative factors associated with major morbidity
Univariable analysis Multivariable analysis
Odds ratio P Odds ratio P
Age (<65 versus 66–75 versus>75 years) 1⋅05 (0⋅63, 1⋅76) 0⋅860
Sex (F versus M) 1⋅56 (0⋅59, 4⋅35) 0⋅398
Differentiation (well–moderate versus poor) 0⋅80 (0⋅41, 1⋅53) 0⋅493
cTNM (1 versus 2 versus 3 versus 4) 0⋅84 (0⋅65, 1⋅08) 0⋅173
Neoadjuvant therapy (no versus yes) 1⋅07 (0⋅53, 2⋅19) 0⋅844
Surgical approach (TTO versus THO) 0⋅77 (0⋅40, 1⋅49) 0⋅444
C-reactive protein (normal versus high) 2⋅37 (0⋅99, 5⋅70) 0⋅054 2⋅86 (1⋅14, 7⋅17) 0⋅025
V̇O2peak (<18⋅6 versus≥18⋅6ml per kg per min) 2⋅65 (1⋅36, 5⋅15) 0⋅004 2⋅92 (1⋅47, 5⋅79) 0⋅002
Anaerobic threshold (<11⋅5 versus≥11⋅5ml per kg per min) 1⋅43 (0⋅73, 2⋅77) 0⋅297
Values in parentheses are 95 per cent confidence intervals. TTO, Transthoracic oesophagectomy; THO, transhiatal oesophagectomy; V̇O2peak, peak oxygen
uptake.
Discussion
Metabolic measures of the SIR together with physiological
measures of cardiorespiratory fitness (V̇O2peak) were inde-
pendently associated with major complications in patients
selected to undergo curative oesophagectomy for adeno-
carcinoma.Major operativemorbidity was threefold higher
in patients with an increased CRP concentration and
poor cardiorespiratory fitness. Combining these parame-
ters established a novel composite risk score (CIPS), from
which six of seven patients (86 per cent) with a score of 2
developed major morbidity compared with 19 of 106 (17⋅9
per cent) with a score of zero.
Previous reports4,29 have contended that the SIR is
closely associated with postoperative complications in col-
orectal cancer, and cardiovascular disease, diabetes, poor
diet, obesity and smoking have all been associated with
increased CRP levels and poorer prognosis.
The present findings raise the possibility that a pro-
gramme of prehabilitation combined with measures to
attenuate the SIR might reduce perioperative complica-
tions. A randomized trial of prehabilitation in elective
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major abdominal surgery30 showed that prehabilitation
reduced postoperative complications by 51 per cent,
and another randomized study31 showed that prehabil-
itation was associated with higher functional capacity
before surgery (mean(s.d.) 6-min walk distance change
36⋅9(51⋅4) m versus−22⋅8(52⋅5) m for no prehabilitation;
P< 0⋅001), which was maintained into the postopera-
tive period (15⋅4(65⋅6) versus−81⋅8(87⋅0) m respectively;
P< 0⋅001).
Using a prehabilitation programme to improve phys-
iological performance and potentially attenuate the SIR
thus seems an attractive proposition, although how best
to do this and understanding which patients will gain
the most benefit are unresolved issues. Incorporating
anti-inflammatory medication into a prehabilitation
care package is not without risk. A meta-analysis32 of
non-steroidal anti-inflammatory use in colorectal surgery
suggested an increased risk of anastomotic leak (OR 1⋅96).
A similar finding was also observed in patients undergoing
oesophagogastrectomy (OR 5⋅24)33. Conversely, two doses
of perioperative dexamethasone reduced the postoperative
inflammatory response and complication rate in patients
undergoing colectomy for cancer34.
The results of the present study merit validation in an
independent cohort, although limitations in its method-
ology mean that these findings must be interpreted with
caution. The patient cohort was a highly selected group
with adenocarcinoma or squamous cell carcinoma, most of
whom had neoadjuvant therapy and surgery, so were not
representative of all patients diagnosed with oesophageal
cancer who undergo operation. Data relating to blood loss
and duration of surgery were not collected, and these may
be important confounders. This analysis did not include
patients who had an open-and-close procedure. Twenty
patients had a laparoscopically assisted oesophagectomy,
and the CIPS will therefore require validation in this sub-
group. The study, however, has several strengths. Patients
were recruited from a consecutive series of patients diag-
nosed with oesophageal cancer, from a single UK geo-
graphical region, all treated by the same specialist team,
using a standardized staging algorithm and team-based
operative techniques, with international audited and pub-
lished quality control35.
Combining CRP level and V̇O2peak into a novel prognos-
tic score has disclosed a subset of patients at high risk of
developing complications. Refining cardiopulmonary fit-
ness by using a multimodal prehabilitation treatment bun-
dle that might attenuate the SIR and reduce postoperative
morbidity seems an attractive approach for patients under-
going oesphagectomy for cancer.
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